Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EPS (Weighted Average and Diluted) (2020 - 2024)

Immuneering has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.59 for Q4 2024.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.59 for Q4 2024, down 13.46% from a year ago — trailing twelve months through Dec 2024 was -$2.04 (down 7.94% YoY), and the annual figure for FY2025 was -$1.27, up 37.75%.
  • EPS (Weighted Average and Diluted) for Q4 2024 was -$0.59 at Immuneering, down from -$0.49 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for IMRX hit a ceiling of -$0.05 in Q4 2021 and a floor of -$1.61 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.49 (2022), compared with a mean of -$0.63.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 95.76% in 2021 and later tumbled 900.0% in 2022.
  • Immuneering's EPS (Weighted Average and Diluted) stood at -$1.18 in 2020, then soared by 95.76% to -$0.05 in 2021, then tumbled by 900.0% to -$0.5 in 2022, then dropped by 4.0% to -$0.52 in 2023, then dropped by 13.46% to -$0.59 in 2024.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.59 (Q4 2024), -$0.49 (Q3 2024), and -$0.47 (Q2 2024) per Business Quant data.